Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor

被引:0
作者
Jian Zhang
Nicholas P. McAndrew
Xiaojia Wang
Yiqun Du
Brian DiCarlo
Mei Wang
Kan Chen
Wenlei Yu
Xichun Hu
机构
[1] Fudan University Shanghai Cancer Center,Phase I Clinical Trial Center
[2] Fudan University,Department of Oncology, Shanghai Medical College
[3] UCLA David Geffen School of Medicine,Division of Hematology/Oncology
[4] Zhejiang Cancer Hospital,Department of Medical Oncology
[5] Dizal Pharmaceutical,undefined
[6] Fudan University Shanghai Cancer Center,undefined
来源
Breast Cancer Research | / 25卷
关键词
HER2; Tyrosine kinase inhibitor; Blood–brain barrier; Breast cancer; Central nervous system metastases;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 124 条
[41]  
Brufsky AM(undefined)undefined undefined undefined undefined-undefined
[42]  
Mayer M(undefined)undefined undefined undefined undefined-undefined
[43]  
Rugo HS(undefined)undefined undefined undefined undefined-undefined
[44]  
Kaufman PA(undefined)undefined undefined undefined undefined-undefined
[45]  
Tan-Chiu E(undefined)undefined undefined undefined undefined-undefined
[46]  
Tripathy D(undefined)undefined undefined undefined undefined-undefined
[47]  
Hurvitz SA(undefined)undefined undefined undefined undefined-undefined
[48]  
O'Shaughnessy J(undefined)undefined undefined undefined undefined-undefined
[49]  
Mason G(undefined)undefined undefined undefined undefined-undefined
[50]  
Yardley DA(undefined)undefined undefined undefined undefined-undefined